Multiple Myeloma — Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients
Citation(s)
A Phase I/IIA, Non-Randomized, Open Label, Single Dose, Dose-Escalation, Safety Study of BKT140, a CXCR4 Antagonist in Patients With Multiple Myeloma